Home › Merck Announces FDA Accepts Samsung Bioepis Biologics License Application (BLA) for SB2 (Infliximab), an Investigational Biosimilar of Remicade
 

Keywords :   


Merck Announces FDA Accepts Samsung Bioepis Biologics License Application (BLA) for SB2 (Infliximab), an Investigational Biosimilar of Remicade

2016-05-24 01:50:08| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. First BLA Filed by Samsung Bioepis as Part of Its Partnership with Merck KENILWORTH, N.J. Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) submitted by Samsung Bioepis Co., Ltd. for SB2 (infliximab), an investigational biosimilar candidate of Remicade. Language: English read more

Tags: of application license samsung

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
24.11MSX2
24.11CITY 1-13
24.11 Loveyoursself Soul DVD
24.11B787-8 1/400
24.11GIANT CONTEND SL1105
24.11HappySanrio characters Halloween
24.11
24.11emmi
More »